Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant
Public ClinicalTrials.gov record NCT04693637. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ALVR105 (Viralym-M) Compared to Placebo for the Prevention of AdV, BKV, CMV, EBV, HHV-6, and JCV Infection and/or Disease, in High-Risk Patients After Allogeneic Hematopoietic Cell Transplant
Study identification
- NCT ID
- NCT04693637
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Lead sponsor
- AlloVir
- Industry
- Enrollment
- 26 participants
Conditions and interventions
Conditions
Interventions
- Posoleucel (ALVR105) Biological
Biological
Eligibility (public fields only)
- Age range
- 1 Year and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 14, 2021
- Primary completion
- Jan 18, 2023
- Completion
- Jan 18, 2023
- Last update posted
- May 8, 2024
2021 – 2023
United States locations
- U.S. sites
- 16
- U.S. states
- 13
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35233 | — |
| City of Hope National Medical Center | Duarte | California | 91010 | — |
| University of California, San Francisco Medical Center | San Francisco | California | 94143 | — |
| Childrens National Medical Center | Northwest Rectangle | District of Columbia | 20010 | — |
| Indiana University Melvin and Bren Simon Cancer Center | Indianapolis | Indiana | 46202 | — |
| University of Kansas Hospital | Westwood | Kansas | 66205 | — |
| University of Maryland Medical Center | Baltimore | Maryland | 21201 | — |
| The Johns Hopkins Hospital | Baltimore | Maryland | 21287 | — |
| University of Minnesota | Minneapolis | Minnesota | 55455 | — |
| Children's Mercy Kansas City | Kansas City | Missouri | 64108 | — |
| Weill Cornell Medical College | New York | New York | 10065 | — |
| Stony Brook University Hospital Cancer Center | Stony Brook | New York | 11794 | — |
| Nationwide Children's Hospital | Columbus | Ohio | 43205 | — |
| Children's Medical Center Dallas | Dallas | Texas | 75235 | — |
| University of Virginia | Charlottesville | Virginia | 22908 | — |
| Fred Hutchinson Cancer Research Center | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04693637, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 8, 2024 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04693637 live on ClinicalTrials.gov.